Clinical Trials

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

252 enrolled

Nasopharyngeal Carcinoma

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

516 enrolled

Nasopharyngeal Cancinoma (NPC)

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Nasopharyngeal Carcinoma

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

400 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

264 enrolled

Nasopharyngeal Carcinoma

NCT02611960 2023-07-13

Keynote-122

233 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Nasopharyngeal Neoplasms

NCT02940925 2023-04-12

TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma

241 enrolled

Nasopharyngeal Carcinoma

NCT05717764 2023-02-08

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

500 enrolled

Nasopharyngeal Carcinoma

NCT02460419 2022-10-28

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

104 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

556 enrolled

Nasopharyngeal Carcinoma

NCT05044117 2022-03-03

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

220 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT00379262 2019-08-07

Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

803 enrolled

Nasopharyngeal Carcinoma

NCT02958111 2019-06-12

CAN

406 enrolled

Nasopharyngeal Carcinoma

NCT03503136 2018-05-11

NX-NPC

632 enrolled

Nasopharyngeal Carcinoma

NCT02786641 2016-06-01

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

235 enrolled

Nasopharyngeal Carcinoma

NCT02633176 2015-12-17

Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

120 enrolled

Nasopharyngeal Carcinoma

NCT02621970 2015-12-04

Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma

534 enrolled